US FDA Leadership Team: Woodcock’s Next Chapter
The announcement of US FDA Deputy Commissioner’s new focus going forward at the agency may not mean what you think it does. The focus shouldn’t be on what Janet Woodcock is not doing – but on the fact that she is staying on at the agency at all.
You may also be interested in...
Commissioner Robert Califf wants Woodcock to improve food operations and processes, but lawmakers question whether she is the best overseer for the area.
To help with the transition to Biden’s COVID-19 response, Woodcock will retain some therapeutic development duties in the program the Trump administration had called Operation Warp Speed.
The elevation of the US FDA’s top drug regulator, Janet Woodcock, to oversee COVID-19 response efforts is being framed a temporary step as part of the crisis response. But it is also a try-out for the most significant leadership transition in drug regulation in the US in a generation.